The FDA based its approval on positive findings from the phase 3 PACIFIC study (ClinicalTrials.gov Identifier: NCT02125461), for which researchers randomly assigned 713 patients with NSCLC without disease progression after CRT to receive durvalumab 10 mg/kg or placebo.

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.